Walmart has announced a new venture that will bring clinical‑trial sites to four locations across the United States: three former Walmart Health centers that closed in April 2024 and one rural Walmart store that will be converted into a research hub. The company will partner with Care Access, an independent clinical‑research firm, to staff the sites with screening teams that provide health assessments, information on ongoing studies, and assistance with enrollment.
The move is part of Walmart’s broader strategy to diversify beyond retail and pharmacy services. By repurposing existing real‑estate assets, Walmart can reduce the capital outlay required to launch a research operation while tapping into its deep community reach. The initiative also addresses a long‑standing gap in clinical‑trial access for underserved and rural populations, a priority that aligns with the U.S. Food and Drug Administration’s push for greater diversity in study enrollment.
Care Access will manage the day‑to‑day operations of the research sites, while Walmart will provide the physical space, marketing, and community trust that are essential for recruiting participants. The partnership model mirrors approaches used by other retailers such as Walgreens and CVS, positioning Walmart to compete in the growing decentralized‑trial market.
Dr. Emily Aaronson, Walmart’s chief medical officer, said the program “will bring clinical trial opportunities closer to home and reduce participation barriers.” She added that the company believes community‑based research can “shape health outcomes in neighborhoods, towns, and rural communities where people already trust and rely on everyday services.”
The announcement follows Walmart’s earlier decision to close its Walmart Health centers in 2024 due to an unsustainable operating model. Repurposing those sites for research allows the company to leverage the infrastructure it already owns, potentially generating new revenue from drug‑company contracts and government grants while reinforcing Walmart’s image as a health‑care partner.
Industry analysts note that Walmart’s entry into clinical research could accelerate the adoption of decentralized trials, a trend that has gained traction amid the COVID‑19 pandemic. The company’s extensive store network and brand recognition give it a distinct advantage over traditional research institutions, but it will need to navigate regulatory compliance and maintain high data‑quality standards to succeed in this competitive space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.